Home › Amylin's long-delayed diabetes drug gets FDA nod
 

Keywords :   


Amylin's long-delayed diabetes drug gets FDA nod

2012-01-28 02:53:46| Biotech - Topix.net

Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine, Byetta.


Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
22.02Jupiter to loan or grant $380,000 to lure biotech firms
22.02Injectable gel could repair tissue damaged by heart attack
22.02U.S. "Cash Machines" Dominate List of 2011 Value Creators
22.02US top court won't review J&J-Abbott patent case
22.02Johnson & Johnson CEO to step down in April
21.02Omnicare ends hostile bid for PharMerica
21.02Alabama officials monitor outbreak of new virus
21.02FDA staff focus on safety of Forest lung drug
Biotechnology and Pharmaceuticals »
22.02India: Sacred natural sites and climate change threat
22.02Chicago Contractor Rushes To Repair 100-Year-Old Lift Bridge
22.02Construction Week
22.02Foundation Flaws Make Kentucky's Wolf Creek Dam a High-Risk Priority
22.02Beatles Ringtones Added Exclusively to iTunes
22.02Apple iTunes 10.5.3
22.02EU Asks High Court to Decide if ACTA Infringes on Rights
22.02Google Street View Expands to Russia
More »